TruAlt Bioenergy Ltd Q1 FY27 Earnings Analysis
Published 31 May 2026 | Agricultural Food & other Products | Market Cap: ₹4.2K Cr
Price
₹495
Market Cap
₹4.2K Cr
P/E Ratio
28.6
Revenue Rank
Margin Rank
Earnings Summary
- TruAlt Bioenergy aims to achieve a minimum of 40 crore litres ethanol sales volume, with a bonus target of 55 crore litres (Page 23). - TruAlt Bioenergy aims to achieve at least 40 crore litres ethanol sales volume by FY27, with a bonus target of 55 crore litres, reflecting strong volume growth potential.
📊 Revenue & Sales Performance
Rank 2- TruAlt Bioenergy aims to achieve a minimum of 40 crore litres ethanol sales volume, with a bonus target of 55 crore litres (Page 23). - Current ethanol sales run rate is 2.2 crore litres/month; expected increase to about 5 crore litres/month once additional 15 crore litres supply from OMCs is implemented (Page 5). - Revenue run rate target from ethanol is around INR 350-400 crores per month if 6 crore litres capacity is utilized (Page 27). - Execution of 15 crore litres additional ethanol order is pending government/OMC approval, expected after 24-30 months (FY29) (Page 29). - Exploration of export opportunities and sustainable aviation fuel plans to diversify revenue streams and improve capacity utilization (Pages 5, 23, 29). - Compressed Biogas (CBG) business shows strong growth potential with steady 85%+ capacity utilization and EBITDA more than 45%, aiming for phased scaling beyond current 10+4 planned plants (Pages 17, 21). - Fuel retail vertical expected to drive additional revenue growth with 75 planned outlets, seven currently operational showing INR 105 crores revenue from them (Page 18).
📈 Profitability & Margins
Rank 3- TruAlt Bioenergy aims to achieve at least 40 crore litres ethanol sales volume by FY27, with a bonus target of 55 crore litres, reflecting strong volume growth potential. - Additional revenue streams planned from sustainable aviation fuel and ethanol exports to fully utilize ethanol capacity. - CBG business shows high margin potential with expected EBITDA margins around 50-60%; scalability planned through phased capex after current plants stabilize. - Fuel retail vertical expected to expand significantly with plans for about 75 retail outlets, potentially generating substantial incremental revenue. - Management cautious on timelines; new plant commissioning slated for FY29 (24-30 months out), which will bring one-time income after commissioning. - Despite recent challenges and lower EBITDA growth impacting profits, long-term outlook includes diversified revenue streams and increasing blending mandates driving demand. - Marketing and advertisement spend to increase to support fuel retail business expansion, aiding growth. - Overall, earnings expected to grow with volume ramp-up, policy tailwinds, and diversification beyond government subsidies.
🏗️ Capital Expenditure Plans
Yes- TruAlt Bioenergy plans to commission a new plant expected within 24 to 30 months (FY29) for which they will receive a one-shot payment once operational. - They are investing in multiple CBG (Compressed Bio-Gas) plants: 9-10 to be live by current year and 10-15 more planned, funded via a 70:30 debt-to-equity mix. - Funding includes 51% investment from TruAlt and 49% from JV partners Sumitomo and GAIL, with NABARD loans at favorable interest rates (around 8.65%). - A fourth CBG plant is planned pending land clearance, aiming for a total of 11 units. - Expansion into fuel retail vertical with plans for up to 75 outlets to drive future revenue growth. - Investments also target diversification into sustainable aviation fuel and export of ethanol to reduce dependence on government policy.
💰 Fundraising & Capital Structure
Yes- TruAlt Bioenergy plans to fund the expansion of their CBG plants through a mix of debt and equity. - The company will invest 51% equity, while JV partners Sumitomo and GAIL will contribute 49%. - Capital has already been provisioned and infused into subsidiaries for this purpose. - Debt financing has been tied up, notably with NABARD at an interest rate of 8.65% for Sumitomo plans. - The debt-to-equity mix targeted for funding is approximately 70% debt and 30% equity. - Management acknowledged the need for more investor engagement on fundraising updates going forward.
📋 Order Book & Pipeline
No- TruAlt Bioenergy has existing purchase orders (POs) from private OMCs for about 8 crore litres of ethanol, with only 1.6 crore litres supplied so far; balance 6+ crore litres pending lifting due to delay in indent issuance. - A court order dated February 4, 2026, mandates OMCs to lift an additional 15 crore litres within three months; this has not been implemented yet due to ongoing litigation involving LTOA holders and OMCs. - Total expected orderbook for FY 2027 including OMC allocations is approximately 40 crore litres (public + private OMCs) plus pending 15 crore litres from the court order, targeting a peak capacity of around 55 crore litres. - Inventory of nearly INR500 crores is built awaiting order execution. - Implementation of pending orders expected to resume post resolution of related court cases around June to September 2026.
Key Metrics
Revenue
Margin
Capex
Fundraise
Order Book
Frequently Asked Questions
What were TruAlt Bioenergy Ltd Q1 FY27 results?
- TruAlt Bioenergy aims to achieve a minimum of 40 crore litres ethanol sales volume, with a bonus target of 55 crore litres (Page 23). - TruAlt Bioenergy aims to achieve at least 40 crore litres ethanol sales volume by FY27, with a bonus target of 55 crore litres, reflecting strong volume growth potential.
What is TruAlt Bioenergy Ltd share price analysis?
TruAlt Bioenergy Ltd currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 28.6 with a market cap of ₹4,223. Investors should review the full earnings analysis for detailed insights.
Is TruAlt Bioenergy Ltd planning capital expenditure?
- TruAlt Bioenergy plans to commission a new plant expected within 24 to 30 months (FY29) for which they will receive a one-shot payment once operational.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
